banner

TestNews
30 Aug 2018
reg erg erg ertgeqrtg er gerg erg eqargqearg eargerg ergaerg eargeqarg
Read more

World Congress on Parkinson's disease & Related Disorders
15 Nov 2013
Britannia Pharmaceuticals is pleased to announce our final congress in 2013, the XX World Congress on Parkinson’s disease and Related Disorders running from 8-11 December 2013 in Geneva, Switzerland.
Read more

AM IMPAKT - New clinical trial investigates apomorphine injection for resolving debilitating morning akinesia in Parkinson's disease patients
16 Apr 2013
AM IMPAKT, short for Apokyn for Motor IMProvement of Morning AKinesia Trial, is a Phase IV, multi-center, open-label study investigating treatment with APOKYN (APO-go/Apomine) injection to achieve rapid and reliable improvement of motor symptoms in Parkinson’s disease (PD) patients who experience delayed onset of their oral levodopa medication taken upon awakening.
Read more

Britannia Pharmaceuticals launch theparkinsonhub
11 Apr 2013
World Parkinson’s Day 2013 sees the official launch of theparkinsonhub (www.theparkinsonhub.com), an innovative, interactive resource for patients and carers. theparkinsonhub, developed by Britannia Pharmaceuticals, is committed to sharing the latest news and best practice about Parkinson’s disease (PD), with an emphasis on and around mid to late stage PD.
Read more

New International Marketing Director for Britannia Pharmaceuticals Ltd
30 Mar 2013
Britannia Pharmaceuticals (part of the STADA Arzneimittel group of companies) has appointed Robert Wood as Marketing Director, for international markets.
Read more

Experts at EFNS 2012 Symposium believe earlier initiation of continuous dopaminergic stimulation (CDS) therapy is beneficial in advanced Parkinson's disease (PD)
05 Oct 2012
Experts at EFNS 2012 symposium believe earlier initiation of continuous dopaminergic stimulation (CDS) therapy is beneficial in advanced Parkinson's disease (PD).
Read more

Webinar with EURO-INF Project Leader Professor K Ray Chaudhuri discloses significant benefits of apomorphine and intrajejunal levodopa infusion in advanced Parkinson's disease.
25 Jun 2012
Webinar with EURO-INF Project Leader Professor K Ray Chaudhuri discloses significant benefits of apomorphine and intrajejunal levodopa infusion in advanced Parkinson's disease.
Read more

APO-go®: simplifying the challenge of Parkinson’s therapy in advanced disease.
11 May 2012
“Advanced Parkinson’s disease poses one of the biggest challenges in clinical practice. Patients can be affected with a huge range of motor and non-motor symptoms,” according to Professor K Ray Chaudhuri (King’s College Hospital, London and Clinical Director of the National Parkinson Foundation), co-chair of a symposium on the challenges in treating of the advanced states of Parkinson’s disease held at the MDPD Congress in Berlin last week.
Read more

Announcement regarding Marketing Authorization Approval in Japan of Apokyn® Subcutaneous Injection 30 mg (Apomorphine Hydrochloride Hydrate) for Treatment of Parkinson's Disease
02 Apr 2012
Our Japanese Partner, Kyowa Hakko Kirin Co,. Ltd, received confirmation of their Marketing Authorisation for apomorphine injection in Japan on 30th March 2012.
Read more